Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.46 |
| ▸ | BCHE | P06276 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 9/20 | 0.41 |
| ▸ | PPARD | Q03181 | 8/20 | 0.41 |
| ▸ | PPARG | P37231 | 8/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13582202 | 1.00 | ACHE (0.46) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL2234402 | 0.86 | BCHE (0.45) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL13582777 | 0.86 | BCHE (0.45) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL2297379 | 0.84 | BCHE (0.50) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL2233023 | 0.84 | BCHE (0.50) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL2233622 | 0.82 | ACHE (0.50) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL2236041 | 0.82 | BCHE (0.50) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL13582310 | 0.82 | BCHE (0.50) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL13582141 | 0.82 | ACHE (0.50) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL13582750 | 0.81 | BCHE (0.49) | ACHEPTGS2BCHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528897-B9 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2528897-B1 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| EP-2528897-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| WO-2011093524-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | ACHE 3669/4885PTGS2 438/4885BCHE 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.